Clinical Study | Office of Clinical Research

A Study Of Hsp90 Inhibitor At13387 Alone And In Combination With Crizotinib In The Treatment Of Non-Small Cell Lung Cancer (Nsclc)

Posted Date: May 15, 2019

Investigator: Nagla Abdel Karim
Type of Study: Drug

This study is designed to evaluate AT13387 (the study drug) alone or in combination with Crizotinib in subjects with Non-small cell lung cancer (NSCLC). The study drug that will be used in this study, (AT13387), is investigational. This means it has not been approved for use by the United States

Criteria:

To Be Eligible For The Study You Must Have Non-Small Cell Lung Cancer (Nsclc).

Keywords:

Cancer, Lung, At13387-05, Combination, Nsclc

For More Information:

Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List